Linagliptin Ameliorates Methylglyoxal-Induced Peritoneal Fibrosis in Mice

PLoS ONE Volume 11 Issue 8 Page e0160993- published_at 2016-08-11
アクセス数 : 643
ダウンロード数 : 140

今月のアクセス数 : 8
今月のダウンロード数 : 3
File
PLoSONE_11_e0160993.pdf 5.87 MB 種類 : fulltext
Title ( eng )
Linagliptin Ameliorates Methylglyoxal-Induced Peritoneal Fibrosis in Mice
Creator
Nagai Takuo
Irifuku Taisuke
Source Title
PLoS ONE
Volume 11
Issue 8
Start Page e0160993
Abstract
Recent studies have reported increases of methylglyoxal (MGO) in peritoneal dialysis patients, and that MGO-mediated inflammation plays an important role in the development of peritoneal fibrosis through production of transforming growth factor-β1 (TGF-β1). Linagliptin, a dipeptidyl peptidase-4 inhibitor, exerts anti-inflammatory effects independent of blood glucose levels. In this study, we examined whether linagliptin suppresses MGOinduced peritoneal fibrosis in mice. Male C57/BL6 mice were divided into three groups: control, MGO injection plus saline, and MGO injection plus linagliptin (n = 6 per group). Peritoneal fibrosis was induced by daily intraperitoneal injection of saline containing 40 mmol/L MGO for 21 days. Saline was administered intraperitoneally to the control group. Linagliptin (10 mg/kg) or saline were administrated by once-daily oral gavage from 3 weeks before starting MGO injections. Immunohistochemical staining revealed that linagliptin suppressed expression of α-smooth muscle actin and fibroblast-specific protein-1, deposition of type I and III collagen, and macrophage (F4/80) infiltration. Peritoneal equilibration testing showed improved peritoneal functions in mice treated with linagliptin. Peritoneal injection of MGO increased plasma levels of glucagon-like peptide-1 (GLP-1) in mice, and a further increase was observed in linagliptin-treated mice. Although MGO increased plasma glucose levels, linagliptin did not decrease plasma glucose levels. Moreover, linagliptin reduced the TGF-β1 concentration in the peritoneal fluid of MGO-treated mice. GLP-1 receptor (GLP-1R) was expressed in monocytes/macrophages and linagliptin suppressed GLP-1R expression in MGO-injected mice. These results suggest that oral administration of linagliptin ameliorates MGO-induced peritoneal fibrosis.
Descriptions
This work was supported by a grant from Ryokufukai and the Japanese Association of Dialysis Physicians.
Language
eng
Resource Type journal article
Publisher
Public Library of Science
Date of Issued 2016-08-11
Rights
© 2016 Nagai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Publish Type Version of Record
Access Rights open access
Source Identifier
[ISSN] 1932-6203
[DOI] 10.1371/journal.pone.0160993
[DOI] https://doi.org/10.1371/journal.pone.0160993